インターロイキン-18(IL-18)阻害剤のパイプライン・インサイト2019

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DIMR2016403)
■ 英語タイトル:Interleukin-18 (IL-18) Inhibitors -Pipeline Insights, 2019
■ 発行会社/調査会社:DelveInsight
■ 商品コード:DIMR2016403
■ 発行日:2019年版(※最新版はお問い合わせください)
■ 調査対象地域:グローバル
■ 産業分野:製薬
■ ページ数:約60
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後3営業日)
■ 販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥166,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥332,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥532,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[インターロイキン-18(IL-18)阻害剤のパイプライン・インサイト2019]についてメールでお問い合わせはこちら
本調査レポートでは、世界におけるインターロイキン-18(IL-18)阻害剤のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・インターロイキン-18(IL-18)阻害剤の概要
・インターロイキン-18(IL-18)阻害剤のパイプライン概要
・企業別開発中のインターロイキン-18(IL-18)阻害剤
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・インターロイキン-18(IL-18)阻害剤の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・インターロイキン-18(IL-18)阻害剤開発に取り組んでいる企業リスト
・図表一覧
*** レポート概要(サマリー)***

SUMMARY
DelveInsight’s, “Interleukin-18 (IL-18) Inhibitors-Pipeline Insights, 2019”, report provides in depth insights on the pipeline drugs and their development activities around the Interleukin-18 (IL-18) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Interleukin-18 (IL-18) Inhibitors. DelveInsight’s Report also assesses the Interleukin-18 (IL-18) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Interleukin-18 (IL-18) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Interleukin-18 (IL-18) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Interleukin-18 (IL-18) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


*** レポート目次(コンテンツ)***

Table of Contents
• Interleukin-18 (IL-18) Inhibitors Overview
• Interleukin-18 (IL-18) Inhibitors Disease Associated
• Interleukin-18 (IL-18) Inhibitors Pipeline Therapeutics
• Interleukin-18 (IL-18) Inhibitors Therapeutics under Development by Companies
• Interleukin-18 (IL-18) Inhibitors Filed and Phase III Products
• Comparative Analysis
• Interleukin-18 (IL-18) Inhibitors Phase II Products
• Comparative Analysis
• Interleukin-18 (IL-18) Inhibitors Phase I and IND Filed Products
• Comparative Analysis
• Interleukin-18 (IL-18) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Interleukin-18 (IL-18) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Interleukin-18 (IL-18) Inhibitors – Discontinued Products
• Interleukin-18 (IL-18) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Interleukin-18 (IL-18) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Interleukin-18 (IL-18) Inhibitors by Therapy Area, 2019
• Number of Products under Development for Interleukin-18 (IL-18) Inhibitors, 2019
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2019
• Comparative Analysis Phase II Products, 2019
• Comparative Analysis Phase I and IND Filed Products, 2019
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2019
• Drug Candidates Profiles
• Interleukin-18 (IL-18) Inhibitors Assessment by Monotherapy Products
• Interleukin-18 (IL-18) Inhibitors Assessment by Combination Products
• Interleukin-18 (IL-18) Inhibitors Assessment by Route of Administration
• Interleukin-18 (IL-18) Inhibitors Assessment by Stage and Route of Administration
• Interleukin-18 (IL-18) Inhibitors Assessment by Molecule Type
• Interleukin-18 (IL-18) Inhibitors Assessment by Stage and Molecule Type
• Interleukin-18 (IL-18) Inhibitors Therapeutics – Discontinued Products
• Interleukin-18 (IL-18) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2019


List of Figures
• Number of Products under Development for Interleukin-18 (IL-18) Inhibitors by Therapy Area, 2019
• Number of Products under Development for Interleukin-18 (IL-18) Inhibitors, 2019
• Filed and Phase III Products, 2019
• Phase II Products, 2019
• Phase I and IND Filed Products, 2019
• Discovery and Pre-Clinical Stage Products, 2019
• Interleukin-18 (IL-18) Inhibitors Assessment by Monotherapy Products
• Interleukin-18 (IL-18) Inhibitors Assessment by Combination Products
• Interleukin-18 (IL-18) Inhibitors Assessment by Route of Administration
• Interleukin-18 (IL-18) Inhibitors Assessment by Stage and Route of Administration
• Interleukin-18 (IL-18) Inhibitors Assessment by Molecule Type
• Interleukin-18 (IL-18) Inhibitors Assessment by Stage and Molecule Type


*** レポートのキーワード ***

インターロイキン-18(IL-18)阻害剤、医薬品、製薬、研究開発、パイプライン、治療、治験

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIMR2016403 )"インターロイキン-18(IL-18)阻害剤のパイプライン・インサイト2019" (英文:Interleukin-18 (IL-18) Inhibitors -Pipeline Insights, 2019)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。